Bone Biologics Corporation (NasdaqCM: BBLG)
Health Care · Biotechnology · US
$0.60
-3.42% today · -71.0% 1Y
Bone Biologics Corporation (NasdaqCM: BBLG) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.73M and employs 2 people.
Over the last twelve months the share price has lost 71.0%, trading between 0.59 and 4.13.
Tweenvest scores Bone Biologics Corporation across four factors: quality 26/100. Its strongest factor is quality.
BBLG price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.73M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.61
- Dividend yield
- —
- Beta (5Y)
- 0.53
- 52-week high
- $4.13
- 52-week low
- $0.59
- Avg volume (3M)
- —
- Shares outstanding
- 2.76M
- Employees
- 2
- Next earnings
- —
About Bone Biologics Corporation
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
- ISIN
- US0980706008
- Founded
- 2004
- Listed since
- Oct 13, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.